TWI867299B - 用於治療或預防伴隨抗癌劑之投予之傷害的醫藥組合物 - Google Patents
用於治療或預防伴隨抗癌劑之投予之傷害的醫藥組合物 Download PDFInfo
- Publication number
- TWI867299B TWI867299B TW111118516A TW111118516A TWI867299B TW I867299 B TWI867299 B TW I867299B TW 111118516 A TW111118516 A TW 111118516A TW 111118516 A TW111118516 A TW 111118516A TW I867299 B TWI867299 B TW I867299B
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- sod
- superoxide dismutase
- administration
- tumor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-083610 | 2021-05-18 | ||
| JP2021083610 | 2021-05-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202313100A TW202313100A (zh) | 2023-04-01 |
| TWI867299B true TWI867299B (zh) | 2024-12-21 |
Family
ID=84141593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111118516A TWI867299B (zh) | 2021-05-18 | 2022-05-18 | 用於治療或預防伴隨抗癌劑之投予之傷害的醫藥組合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240261375A1 (https=) |
| EP (1) | EP4353251A4 (https=) |
| JP (1) | JP7504367B2 (https=) |
| KR (1) | KR102843447B1 (https=) |
| CN (1) | CN117279657A (https=) |
| AU (1) | AU2022278242B2 (https=) |
| CA (1) | CA3220333A1 (https=) |
| CO (1) | CO2023017275A2 (https=) |
| MX (1) | MX2023013777A (https=) |
| TW (1) | TWI867299B (https=) |
| WO (1) | WO2022244757A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025178511A1 (ru) * | 2024-02-21 | 2025-08-28 | Евгений Владимирович ГРИГОРЬЕВ | Применение супероксиддисмутазы 2 в качестве антиоксиданта в сверхмалых дозировках |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006040980A1 (ja) * | 2004-10-12 | 2006-04-20 | Asahi Glass Company, Limited | レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0653670B2 (ja) * | 1985-10-28 | 1994-07-20 | 日研フ−ド株式会社 | 化学療法剤の副作用低減化剤 |
| JPH04135485A (ja) * | 1990-09-28 | 1992-05-08 | Seikagaku Kogyo Co Ltd | 白金錯体及び抗腫瘍剤 |
| JP3232542B2 (ja) | 1993-01-08 | 2001-11-26 | 宇部興産株式会社 | ヒトＣｕ，Ｚｎ型スーパーオキシドジスムターゼ誘導体及びその製造法 |
| JPH08208511A (ja) * | 1995-01-31 | 1996-08-13 | Samu Kenkyusho:Kk | 抗運動ニューロン疾患剤 |
| US6221848B1 (en) * | 1998-05-11 | 2001-04-24 | University Of Pittsburgh | Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy |
| US20020055467A1 (en) | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
| JP2001002585A (ja) * | 1999-06-22 | 2001-01-09 | Ltt Kenkyusho:Kk | レシチン化スーパーオキシドジスムターゼ含有抗線維化剤 |
| JP3792487B2 (ja) | 1999-06-24 | 2006-07-05 | 株式会社Ｌｔｔバイオファーマ | レシチン化スーパーオキシドジスムターゼ含有医薬組成物 |
| JP2003532691A (ja) | 2000-05-05 | 2003-11-05 | ノボ ノルディスク アクティーゼルスカブ | 重症疾患神経障害 |
| JP2002080395A (ja) * | 2000-08-31 | 2002-03-19 | Ltt Institute Co Ltd | 心筋傷害処置剤 |
| ES2375797T3 (es) | 2003-01-21 | 2012-03-06 | Genervon Biopharmaceuticals Llc | Péptidos y compuestos de factores tróficos de motoneuronas y sus procedimientos de utilización. |
| WO2006050211A2 (en) | 2004-10-28 | 2006-05-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
| JP2006169128A (ja) | 2004-12-13 | 2006-06-29 | Ltt Bio-Pharma Co Ltd | 熱傷治療剤 |
| JP4867540B2 (ja) | 2006-09-20 | 2012-02-01 | 日本精工株式会社 | 無段変速装置 |
| US20100143321A1 (en) * | 2006-12-19 | 2010-06-10 | Ltt Bio Pharma Co., Ltd. | Therapeutic composition for interstitual pneumonia |
| JP5459827B2 (ja) | 2009-03-13 | 2014-04-02 | 株式会社Ｌｔｔバイオファーマ | 慢性閉塞性肺疾患改善剤 |
| EP2637698B1 (en) | 2010-11-09 | 2022-04-20 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US9187509B2 (en) | 2012-01-05 | 2015-11-17 | Pled Pharma AB | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
| JP6545926B2 (ja) * | 2012-11-30 | 2019-07-17 | 株式会社ナノエッグ | 手足症候群治療用組成物 |
| RU2017106172A (ru) | 2014-07-31 | 2018-08-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) |
| EP2985036A3 (en) | 2014-08-14 | 2016-03-09 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | CYP2J2 antagonists in the treatment of pain |
| US11197862B2 (en) | 2015-07-16 | 2021-12-14 | Xomics Biopharma, Inc. | Methods of preventing toxicity of platinum drugs |
| JP6650612B2 (ja) | 2015-10-06 | 2020-02-19 | パナソニックＩｐマネジメント株式会社 | 照明制御装置及び照明システム |
-
2022
- 2022-05-17 CN CN202280033165.1A patent/CN117279657A/zh active Pending
- 2022-05-17 JP JP2023522667A patent/JP7504367B2/ja active Active
- 2022-05-17 US US18/560,442 patent/US20240261375A1/en active Pending
- 2022-05-17 EP EP22804668.6A patent/EP4353251A4/en active Pending
- 2022-05-17 CA CA3220333A patent/CA3220333A1/en active Pending
- 2022-05-17 WO PCT/JP2022/020473 patent/WO2022244757A1/ja not_active Ceased
- 2022-05-17 AU AU2022278242A patent/AU2022278242B2/en active Active
- 2022-05-17 MX MX2023013777A patent/MX2023013777A/es unknown
- 2022-05-17 KR KR1020237038088A patent/KR102843447B1/ko active Active
- 2022-05-18 TW TW111118516A patent/TWI867299B/zh active
-
2023
- 2023-12-14 CO CONC2023/0017275A patent/CO2023017275A2/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006040980A1 (ja) * | 2004-10-12 | 2006-04-20 | Asahi Glass Company, Limited | レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法 |
Non-Patent Citations (3)
| Title |
|---|
| 期刊 Kim ST, et al. Phosphatidylcholine attenuated docetaxel-induced peripheral neurotoxicity in rats. Drug Chem Toxicol. 41 2017/12/06 476-485; * |
| 期刊 Kim ST, et al. Protective effects of phosphatidylcholine on oxaliplatin-induced neuropathy in rats. Life Sci. 130 2015/03/25 81-87; * |
| 期刊 太田 有紀, 武永 美津子, 都倉 享恵, 濱口 明美, 山口 葉子, 中村 雅也, 岡野 栄之, 五十嵐 理慧 外傷性脊髄損傷後のレシチン修飾SOD投与の有用性 Inflammation and Regeneration 26 2006/08/18 113-120 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4353251A1 (en) | 2024-04-17 |
| CN117279657A (zh) | 2023-12-22 |
| US20240261375A1 (en) | 2024-08-08 |
| JP7504367B2 (ja) | 2024-06-24 |
| AU2022278242B2 (en) | 2024-11-14 |
| CO2023017275A2 (es) | 2023-12-20 |
| MX2023013777A (es) | 2023-12-04 |
| TW202313100A (zh) | 2023-04-01 |
| WO2022244757A1 (ja) | 2022-11-24 |
| KR20240008844A (ko) | 2024-01-19 |
| JPWO2022244757A1 (https=) | 2022-11-24 |
| BR112023024140A2 (pt) | 2024-02-06 |
| AU2022278242A1 (en) | 2023-11-30 |
| EP4353251A4 (en) | 2025-05-14 |
| KR102843447B1 (ko) | 2025-08-06 |
| CA3220333A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qiao et al. | Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan | |
| Hu et al. | E Platinum, a newly synthesized platinum compound, induces autophagy via inhibiting phosphorylation of mTOR in gastric carcinoma BGC-823 cells | |
| JP2009504679A (ja) | Ｖｅｇｆアンタゴニストを用いて疾患を処置する方法 | |
| EP3263107B1 (en) | Block copolymer conjugate of physiologically active substance | |
| TWI867299B (zh) | 用於治療或預防伴隨抗癌劑之投予之傷害的醫藥組合物 | |
| Li et al. | A011, a novel small-molecule ligand of σ2 receptor, potently suppresses breast cancer progression via endoplasmic reticulum stress and autophagy | |
| CN114621325A (zh) | 一种纤连蛋白靶向多肽及其在促进肿瘤失巢凋亡及化疗增敏中的应用 | |
| RU2845522C2 (ru) | Фармацевтическая композиция для лечения или профилактики расстройства, связанного с введением противоракового средства | |
| CA2807707A1 (en) | Compositions and methods for treating cancer | |
| JP6629753B2 (ja) | がん治療剤の組合せ | |
| HK40100859A (zh) | 用於治疗或预防伴随抗癌剂给药的障碍的医药组合物 | |
| AU2020255063B2 (en) | Combined use of A-nor-5α androstane compound drug and anticancer drug | |
| CN116234541A (zh) | 通过EpoR拮抗剂治疗疾病 | |
| BR112023024140B1 (pt) | Uso de uma superóxido dismutase lecitinizada para tratar ou prevenir um distúrbio associado com a administração de um agente anticâncer | |
| KR20220001246A (ko) | 췌장암 예방 또는 치료용 조성물 | |
| HK1212920A1 (zh) | 使用麦胶蛋白肽治疗癌症的套件和方法 | |
| US11980667B2 (en) | Short TAT oligomers for drug delivery | |
| WO2024148356A1 (en) | Nanoparticle-nhe3 peptide to treat diarrhea | |
| KR20250022385A (ko) | 말초신경 퇴행성 질환의 예방 또는 치료용 약학 조성물 | |
| CN112294829A (zh) | 红景天苷在制备治疗或预防癌症的药物中的应用 | |
| HK40008907A (en) | Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients | |
| BR112018010535B1 (pt) | Compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor | |
| WO2014020211A1 (es) | Línea celular de cáncer de mama y su uso en la identificación de compuestos candidatos para el tratamiento de dicha enfermedad |